These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26247532)

  • 21. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
    Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
    Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.
    La Rosa S; Adsay V; Albarello L; Asioli S; Casnedi S; Franzi F; Marando A; Notohara K; Sessa F; Vanoli A; Zhang L; Capella C
    Am J Surg Pathol; 2012 Dec; 36(12):1782-95. PubMed ID: 23026929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms.
    Xu JZ; Wang WQ; Zhang SR; Xu HX; Wu CT; Qi ZH; Gao HL; Ni QX; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Mar; 25(3):647-654. PubMed ID: 29235006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
    Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
    Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sporadic Small (≤20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis.
    Ricci C; Casadei R; Taffurelli G; Pacilio CA; Campana D; Ambrosini V; Donatella S; Minni F
    Ann Surg Oncol; 2017 Sep; 24(9):2603-2610. PubMed ID: 28681158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.
    Jin F; Wang K; Qin TT; Li X; Guo F; Ma GN; Hu XH; Han P
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):587-595. PubMed ID: 28786064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
    Zhou B; Fang B; Yan S; Wang W
    Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.
    Haugvik SP; Kaemmerer D; Gaujoux S; Labori KJ; Verbeke CS; Gladhaug IP
    Curr Oncol Rep; 2016 May; 18(5):28. PubMed ID: 26984415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive Effect of the Total Number of Examined Lymph Nodes on N Staging and Survival in Pancreatic Neuroendocrine Neoplasms.
    Zhang X; Lu L; Liu P; Cao F; Wei Y; Ma L; Gong P
    Pancreas; 2018 Feb; 47(2):183-189. PubMed ID: 29329160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on surgical treatment of pancreatic neuroendocrine neoplasms.
    D'Haese JG; Tosolini C; Ceyhan GO; Kong B; Esposito I; Michalski CW; Kleeff J
    World J Gastroenterol; 2014 Oct; 20(38):13893-8. PubMed ID: 25320524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study.
    Paik WH; Lee HS; Lee KJ; Jang SI; Lee WJ; Hwang JH; Cho CM; Park CH; Han J; Woo SM; Jeong S; Chon HK; Kim TN; Lee JK; Han JH; Yoon JH; Kim YT; Cho JH
    Pancreatology; 2021 Jan; 21(1):208-214. PubMed ID: 33281058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors.
    Furukori M; Imai K; Karasaki H; Watanabe K; Oikawa K; Miyokawa N; Taniguchi M; Furukawa H
    World J Gastroenterol; 2014 Dec; 20(47):17949-54. PubMed ID: 25548493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors.
    Gentil Perret A; Mosnier JF; Buono JP; Berthelot P; Chipponi J; Balique JG; Cuilleret J; Dechelotte P; Boucheron S
    Am J Clin Pathol; 1998 Mar; 109(3):286-93. PubMed ID: 9495200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
    Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
    Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.